Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.
Olmo
M
M
Hospital de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. molmo@csub.scs.es
Ferrer
E
E
Curto
J
J
Barragán
P
P
Saumoy
M
M
Perulero
N
N
Podzamczer
D
D
D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D011788:Quality of Life; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir